SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3127)10/28/2020 10:25:35 PM
From: Biotechwantabe  Read Replies (1) | Respond to of 3557
 
If hospitalized efficacy is good then initial 300k can be allocated to most sick/save lives.

I’m guessing that the nih will wait for clinical results on hospitalized before EUA or before using doses on outpatients. Can’t be that much longer.

Mr. market needs to see a bigger contract from nih. Plus need to see plan for more doses manufactured. Time for Len to make deals.



To: Miljenko Zuanic who wrote (3127)11/4/2020 11:45:02 AM
From: Biotechwantabe  Read Replies (2) | Respond to of 3557
 
Looks like mr. market is more concerned about election results than buying good growth companies.

Not expecting any surprises tomorrow

Eylea ex us flat
Eylea us - guessing flat to +2%
Dupi +70%
Libtayo continue to grind higher

EUA HOPEFULLY next week.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News